Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аденомиоз: фокус на терапию
Аденомиоз: фокус на терапию
Аденомиоз: фокус на терапию. Гинекология. 2019; 21 (5): 16–19.
DOI: 10.26442/20795696.2019.5.190749
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Влияние аденомиоза на репродуктивное здоровье женщины крайне негативно. Отсутствие медикаментозной терапии повышает вероятность хирургического лечения, которое может стать весьма травматичным для пациентки и привести к снижению овариального резерва и фертильности, а также более раннему наступлению менопаузы. Именно поэтому крайне важно своевременно начинать терапию, важнейшим методом которой становится гормональное лечение.
В статье рассмотрен профиль эффективности и безопасности прогестина диеногеста.
Ключевые слова: диеногест, аденомиоз, бесплодие, менопауза.
Key words: dienogest, adenomyosis, infertility, menopause.
В статье рассмотрен профиль эффективности и безопасности прогестина диеногеста.
Ключевые слова: диеногест, аденомиоз, бесплодие, менопауза.
________________________________________________
Key words: dienogest, adenomyosis, infertility, menopause.
Полный текст
Список литературы
1. Гинекология. Под ред. Г.М. Савельевой, Г.Т. Сухих, В.Н. Серова и др. М.: ГЭОТАР-Медиа, 2017.
[Gynecology. Ed. G.M. Savel'eva, G.T. Sukhikh, V.N. Serov et al. Moscow: GEOTAR-Media, 2017 (in Russian).]
2. Pinzauti S, Lazzeri L, Tosti С et al. Transvaginal sonographic features of diffuse adenomyosis in 18–30-year-old nulligravid women without endometriosis: Association with symptoms. Ultrasound Obstet Gynecol 2015; 46: 730–6.
3. Naftalin J, Hoo W, Pateman K et al. How common is adenomyosis? A prospective study of prevalence using transvaginal ultrasound in a gynaecology clinic. Hum Reprod 2012; 27: 3432–9.
4. Chapron C, Tosti C, Marcellin L et al. Relationship between the magnetic resonance imaging appearance of adenomyosis and endometriosis phenotypes. Hum Reprod 2017; 32: 1393–401.
5. Puente JM, Fabris A, Patel J et al. Adenomyosis in infertile women: prevalence and the role of 3D ultrasound as a marker of severity of the disease. Reprod Biol Endocrinol 2016; 14: 60.
6. Kunz C et al. Adenomyosis in endometriosis-prevalence and impact on Fertility. Evidence From magnetic resonance imaging. Hum Reprod 2005; 20 (8): 2309–16.
7. Vered H. Eisenberg et al. Sonographic Signs oF Adenomyosis Are Prevalent in Women Undergoing Surgery For Endometriosis and May Suggest a Higher Risk oF Infertility. BioMed Res Int 2017; Article ID 8967803.
8. Tremellen K, Thalluri V. Impact of adenomyosis on pregnancy rates in IVF treatment. Reprod Biomed Online 2013; 26 (3): 299–300.
9. Bruun MR et al. Endometriosis and adenomyosis are associated with increased risk of preterm delivery and a small for gestational age child: A systematic review and meta-analysis. Acta Obstet Gynecol Scand 2018; 97 (9):1073–90. DOI: 10.1111/aogs.13364
10. Krentel et al. 2013.
11. Yeh C-C et al. Women with adenomyosis are at higher risks of endometrial and thyroid cancers: A population-based historical cohort study. PLoS ONE 2018.
12. Vannuccini S, Tosti C, Carmona F et al. Pathogenesis of adenomyosis: An update on molecular mechanisms. Reprod Biomed Online 2017; 35: 592–601.
13. Linda М et al. Experience oFSymptoms and Disease Impact in Patients with Adenomyosis Patient. DOI: https://doi.org/10.1007/s40271-017-0284-2
14. Llarena N, Flyckt R. Strategies to preserve and optimize Fertility For patients with endometriosis. J Endom Pelvic Pain Dysord 2017; 9 (2): 98–104.
15. Maignien C, Santulli P, Gayet V et al. Prognostic Factors For assisted reproductive technology in women with endometriosis-related infertility. Am J Obstet Gynecol 2017; 216 (280): e1-9.
16. Abdul Karim AK, Shafiee MN, Abd Aziz NH et al. Reviewing the role of progesterone therapy in endometriosis. Gynecol Endocrinol 2019; 35 (1): 10–6.
17. Академия эндометриоза. Вып. №15.
[Academy of Endometriosis. Vol. No. 15. (in Russian).]
18. Vannuccini S et al. Role of medical therapy in the management of uterine adenomyosis. Fertil Steril 2018; 109 (3).
19. Yutaka Osuga, Haruka Fujimoto-Okabe, Atsushi Hagino. Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study. Fertil Steril 2017; 108 (4): 673–8.
20. Osuga Y, Watanabe M, Hagino A. Long-term use of dienogest in the treatment of painful symptoms in adenomyosis. J Obstet Gynaecol Res 2017; 43 (9): 1441–8.
21. Neriishi K et al. Long term dienogest administration in patients with symptomatic adenomyosis. J Obstet Gynaecol Res 2018; 44 (8):
1439–44. DOI: 10.1111/jog.13674
22. Vartanyan E et al. Endometriosis management prior to IVF. Gyn Endocrinol 2015; 21 (Suppl. 1): 42–5.
23. Вартанян Э.Д. и др. Консервативная терапия эндометриоза при подготовке к лечению бесплодия методом экстракорпорального оплодотворения. Гинекология. Эндокринология. 2015; 102 (1): 21–5.
[Vartanian E.D. et al. Konservativnaia terapiia endometrioza pri podgotovke k lecheniiu besplodiia metodom ekstrakorporal'nogo oplodotvoreniia. Ginekologiia. Endokrinologiia. 2015; 102 (1): 21–5. (in Russian).]
24. Кulvasaari P et al. Effect of endometriosis on IFV/ICSI outcome: stage III/IV endometriosis worsens cumulative pregnancy and live-born rates. Hum Reprod 2005; 20 (11): 3130–5.
25. Академия эндометриоза. Вып. №19.
[Academy of Endometriosis. Vol. No. 19. (in Russian).]
26. Grandi G, Mueller M, Bersinger NA et al. Does dienogest influence the inflammatory response of endometriotic cells? A systematic review. Inflammat Res 2016; 65 (3): 183–92.
27. Louise E. Glover. Uterine natural killer cell progenitor populations predict successFul implantation in women with endometriosis-associated infertility. Am J Reprod Immunol 2018; 79: e12817.
28. Prathoomthong, Saowapak et al. The Effects of Dienogest on Macrophage and Natural Killer Cells in Adenomyosis: A Randomized Controlled Study. Int J Fertil Steril 2018; 11 (4): 279.
29. Балан В.Е. и др. Неинвазивные маркеры эндометриоза и динамика их уровня на фоне гормональной терапии. Проблемы репродукции. 2018; 5.
[Balan V.E. et al. Neinvazivnye markery endometrioza i dinamika ikh urovnia na fone gormonal'noi terapii. Problemy reproduktsii. 2018; 5 (in Russian).]
30. Vercellini P et al. Estrogen-progestins and progestins For the management of endometriosis. Fertil and Steril 2016; 106 (7).
31. Yarmolinskay M et al. Poster at SEUD, 12–14 May 2016, Barcelona.
32. Park SY et al. Clin Reprod Med 2016; 43: 215–20.
33. Petraglia F et al. Arch Gynecol Obstet 2012; 285: 167–73.
34. Ota Y et al. J Endometr Pelvic Pain Disord 2015; 7: 63–7.
35. Momoeda M et al. J Obstet Gynaecol Res 2009; 35: 1069–76.
36. Sugimoto K et al. J Obstet Gynaecol Res 2015; 41:1921–26.
37. Roemer T. Poster 1575 at SEUD 12–14 May 2016, Barcelona.
38. Kitawaki J et al. Eur J Obstet Gynecol Biol 2011; 157: 212–16.
39. Takagi H et al. Abstract 0671 at FIGO, 7–12 October 2012, Rome.
40. Kim SH. Poster at SEUD, 25–28 April 2018, Flolence.
41. Lee BS. Poster at SEUD, 25–28 April 2018, Flolence.
42. Imthurn B. Poster at SEUD, 25–28 april 2018, Flolence.
43. Клинические рекомендации по лечению эндометриоза. Минздрав России, 2016.
[Klinicheskie rekomendatsii po lecheniiu endometrioza. Minzdrav Rossii, 2016 (in Russian).]
2. Pinzauti S, Lazzeri L, Tosti С et al. Transvaginal sonographic features of diffuse adenomyosis in 18–30-year-old nulligravid women without endometriosis: Association with symptoms. Ultrasound Obstet Gynecol 2015; 46: 730–6.
3. Naftalin J, Hoo W, Pateman K et al. How common is adenomyosis? A prospective study of prevalence using transvaginal ultrasound in a gynaecology clinic. Hum Reprod 2012; 27: 3432–9.
4. Chapron C, Tosti C, Marcellin L et al. Relationship between the magnetic resonance imaging appearance of adenomyosis and endometriosis phenotypes. Hum Reprod 2017; 32: 1393–401.
5. Puente JM, Fabris A, Patel J et al. Adenomyosis in infertile women: prevalence and the role of 3D ultrasound as a marker of severity of the disease. Reprod Biol Endocrinol 2016; 14: 60.
6. Kunz C et al. Adenomyosis in endometriosis-prevalence and impact on Fertility. Evidence From magnetic resonance imaging. Hum Reprod 2005; 20 (8): 2309–16.
7. Vered H. Eisenberg et al. Sonographic Signs oF Adenomyosis Are Prevalent in Women Undergoing Surgery For Endometriosis and May Suggest a Higher Risk oF Infertility. BioMed Res Int 2017; Article ID 8967803.
8. Tremellen K, Thalluri V. Impact of adenomyosis on pregnancy rates in IVF treatment. Reprod Biomed Online 2013; 26 (3): 299–300.
9. Bruun MR et al. Endometriosis and adenomyosis are associated with increased risk of preterm delivery and a small for gestational age child: A systematic review and meta-analysis. Acta Obstet Gynecol Scand 2018; 97 (9):1073–90. DOI: 10.1111/aogs.13364
10. Krentel et al. 2013.
11. Yeh C-C et al. Women with adenomyosis are at higher risks of endometrial and thyroid cancers: A population-based historical cohort study. PLoS ONE 2018.
12. Vannuccini S, Tosti C, Carmona F et al. Pathogenesis of adenomyosis: An update on molecular mechanisms. Reprod Biomed Online 2017; 35: 592–601.
13. Linda М et al. Experience oFSymptoms and Disease Impact in Patients with Adenomyosis Patient. DOI: https://doi.org/10.1007/s40271-017-0284-2
14. Llarena N, Flyckt R. Strategies to preserve and optimize Fertility For patients with endometriosis. J Endom Pelvic Pain Dysord 2017; 9 (2): 98–104.
15. Maignien C, Santulli P, Gayet V et al. Prognostic Factors For assisted reproductive technology in women with endometriosis-related infertility. Am J Obstet Gynecol 2017; 216 (280): e1-9.
16. Abdul Karim AK, Shafiee MN, Abd Aziz NH et al. Reviewing the role of progesterone therapy in endometriosis. Gynecol Endocrinol 2019; 35 (1): 10–6.
17. Academy of Endometriosis. Vol. No. 15. (in Russian).
18. Vannuccini S et al. Role of medical therapy in the management of uterine adenomyosis. Fertil Steril 2018; 109 (3).
19. Yutaka Osuga, Haruka Fujimoto-Okabe, Atsushi Hagino. Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study. Fertil Steril 2017; 108 (4): 673–8.
20. Osuga Y, Watanabe M, Hagino A. Long-term use of dienogest in the treatment of painful symptoms in adenomyosis. J Obstet Gynaecol Res 2017; 43 (9): 1441–8.
21. Neriishi K et al. Long term dienogest administration in patients with symptomatic adenomyosis. J Obstet Gynaecol Res 2018; 44 (8):
1439–44. DOI: 10.1111/jog.13674
22. Vartanyan E et al. Endometriosis management prior to IVF. Gyn Endocrinol 2015; 21 (Suppl. 1): 42–5.
23. Vartanian E.D. et al. Konservativnaia terapiia endometrioza pri podgotovke k lecheniiu besplodiia metodom ekstrakorporal'nogo oplodotvoreniia. Ginekologiia. Endokrinologiia. 2015; 102 (1): 21–5. (in Russian).
24. Кulvasaari P et al. Effect of endometriosis on IFV/ICSI outcome: stage III/IV endometriosis worsens cumulative pregnancy and live-born rates. Hum Reprod 2005; 20 (11): 3130–5.
25. Academy of Endometriosis. Vol. No. 19. (in Russian).
26. Grandi G, Mueller M, Bersinger NA et al. Does dienogest influence the inflammatory response of endometriotic cells? A systematic review. Inflammat Res 2016; 65 (3): 183–92.
27. Louise E. Glover. Uterine natural killer cell progenitor populations predict successFul implantation in women with endometriosis-associated infertility. Am J Reprod Immunol 2018; 79: e12817.
28. Prathoomthong, Saowapak et al. The Effects of Dienogest on Macrophage and Natural Killer Cells in Adenomyosis: A Randomized Controlled Study. Int J Fertil Steril 2018; 11 (4): 279.
29. Balan V.E. et al. Neinvazivnye markery endometrioza i dinamika ikh urovnia na fone gormonal'noi terapii. Problemy reproduktsii. 2018; 5 (in Russian).
30. Vercellini P et al. Estrogen-progestins and progestins For the management of endometriosis. Fertil and Steril 2016; 106 (7).
31. Yarmolinskay M et al. Poster at SEUD, 12–14 May 2016, Barcelona.
32. Park SY et al. Clin Reprod Med 2016; 43: 215–20.
33. Petraglia F et al. Arch Gynecol Obstet 2012; 285: 167–73.
34. Ota Y et al. J Endometr Pelvic Pain Disord 2015; 7: 63–7.
35. Momoeda M et al. J Obstet Gynaecol Res 2009; 35: 1069–76.
36. Sugimoto K et al. J Obstet Gynaecol Res 2015; 41:1921–26.
37. Roemer T. Poster 1575 at SEUD 12–14 May 2016, Barcelona.
38. Kitawaki J et al. Eur J Obstet Gynecol Biol 2011; 157: 212–16.
39. Takagi H et al. Abstract 0671 at FIGO, 7–12 October 2012, Rome.
40. Kim SH. Poster at SEUD, 25–28 April 2018, Flolence.
41. Lee BS. Poster at SEUD, 25–28 April 2018, Flolence.
42. Imthurn B. Poster at SEUD, 25–28 april 2018, Flolence.
43. Klinicheskie rekomendatsii po lecheniiu endometrioza. Minzdrav Rossii, 2016 (in Russian).
[Gynecology. Ed. G.M. Savel'eva, G.T. Sukhikh, V.N. Serov et al. Moscow: GEOTAR-Media, 2017 (in Russian).]
2. Pinzauti S, Lazzeri L, Tosti С et al. Transvaginal sonographic features of diffuse adenomyosis in 18–30-year-old nulligravid women without endometriosis: Association with symptoms. Ultrasound Obstet Gynecol 2015; 46: 730–6.
3. Naftalin J, Hoo W, Pateman K et al. How common is adenomyosis? A prospective study of prevalence using transvaginal ultrasound in a gynaecology clinic. Hum Reprod 2012; 27: 3432–9.
4. Chapron C, Tosti C, Marcellin L et al. Relationship between the magnetic resonance imaging appearance of adenomyosis and endometriosis phenotypes. Hum Reprod 2017; 32: 1393–401.
5. Puente JM, Fabris A, Patel J et al. Adenomyosis in infertile women: prevalence and the role of 3D ultrasound as a marker of severity of the disease. Reprod Biol Endocrinol 2016; 14: 60.
6. Kunz C et al. Adenomyosis in endometriosis-prevalence and impact on Fertility. Evidence From magnetic resonance imaging. Hum Reprod 2005; 20 (8): 2309–16.
7. Vered H. Eisenberg et al. Sonographic Signs oF Adenomyosis Are Prevalent in Women Undergoing Surgery For Endometriosis and May Suggest a Higher Risk oF Infertility. BioMed Res Int 2017; Article ID 8967803.
8. Tremellen K, Thalluri V. Impact of adenomyosis on pregnancy rates in IVF treatment. Reprod Biomed Online 2013; 26 (3): 299–300.
9. Bruun MR et al. Endometriosis and adenomyosis are associated with increased risk of preterm delivery and a small for gestational age child: A systematic review and meta-analysis. Acta Obstet Gynecol Scand 2018; 97 (9):1073–90. DOI: 10.1111/aogs.13364
10. Krentel et al. 2013.
11. Yeh C-C et al. Women with adenomyosis are at higher risks of endometrial and thyroid cancers: A population-based historical cohort study. PLoS ONE 2018.
12. Vannuccini S, Tosti C, Carmona F et al. Pathogenesis of adenomyosis: An update on molecular mechanisms. Reprod Biomed Online 2017; 35: 592–601.
13. Linda М et al. Experience oFSymptoms and Disease Impact in Patients with Adenomyosis Patient. DOI: https://doi.org/10.1007/s40271-017-0284-2
14. Llarena N, Flyckt R. Strategies to preserve and optimize Fertility For patients with endometriosis. J Endom Pelvic Pain Dysord 2017; 9 (2): 98–104.
15. Maignien C, Santulli P, Gayet V et al. Prognostic Factors For assisted reproductive technology in women with endometriosis-related infertility. Am J Obstet Gynecol 2017; 216 (280): e1-9.
16. Abdul Karim AK, Shafiee MN, Abd Aziz NH et al. Reviewing the role of progesterone therapy in endometriosis. Gynecol Endocrinol 2019; 35 (1): 10–6.
17. Академия эндометриоза. Вып. №15.
[Academy of Endometriosis. Vol. No. 15. (in Russian).]
18. Vannuccini S et al. Role of medical therapy in the management of uterine adenomyosis. Fertil Steril 2018; 109 (3).
19. Yutaka Osuga, Haruka Fujimoto-Okabe, Atsushi Hagino. Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study. Fertil Steril 2017; 108 (4): 673–8.
20. Osuga Y, Watanabe M, Hagino A. Long-term use of dienogest in the treatment of painful symptoms in adenomyosis. J Obstet Gynaecol Res 2017; 43 (9): 1441–8.
21. Neriishi K et al. Long term dienogest administration in patients with symptomatic adenomyosis. J Obstet Gynaecol Res 2018; 44 (8):
1439–44. DOI: 10.1111/jog.13674
22. Vartanyan E et al. Endometriosis management prior to IVF. Gyn Endocrinol 2015; 21 (Suppl. 1): 42–5.
23. Вартанян Э.Д. и др. Консервативная терапия эндометриоза при подготовке к лечению бесплодия методом экстракорпорального оплодотворения. Гинекология. Эндокринология. 2015; 102 (1): 21–5.
[Vartanian E.D. et al. Konservativnaia terapiia endometrioza pri podgotovke k lecheniiu besplodiia metodom ekstrakorporal'nogo oplodotvoreniia. Ginekologiia. Endokrinologiia. 2015; 102 (1): 21–5. (in Russian).]
24. Кulvasaari P et al. Effect of endometriosis on IFV/ICSI outcome: stage III/IV endometriosis worsens cumulative pregnancy and live-born rates. Hum Reprod 2005; 20 (11): 3130–5.
25. Академия эндометриоза. Вып. №19.
[Academy of Endometriosis. Vol. No. 19. (in Russian).]
26. Grandi G, Mueller M, Bersinger NA et al. Does dienogest influence the inflammatory response of endometriotic cells? A systematic review. Inflammat Res 2016; 65 (3): 183–92.
27. Louise E. Glover. Uterine natural killer cell progenitor populations predict successFul implantation in women with endometriosis-associated infertility. Am J Reprod Immunol 2018; 79: e12817.
28. Prathoomthong, Saowapak et al. The Effects of Dienogest on Macrophage and Natural Killer Cells in Adenomyosis: A Randomized Controlled Study. Int J Fertil Steril 2018; 11 (4): 279.
29. Балан В.Е. и др. Неинвазивные маркеры эндометриоза и динамика их уровня на фоне гормональной терапии. Проблемы репродукции. 2018; 5.
[Balan V.E. et al. Neinvazivnye markery endometrioza i dinamika ikh urovnia na fone gormonal'noi terapii. Problemy reproduktsii. 2018; 5 (in Russian).]
30. Vercellini P et al. Estrogen-progestins and progestins For the management of endometriosis. Fertil and Steril 2016; 106 (7).
31. Yarmolinskay M et al. Poster at SEUD, 12–14 May 2016, Barcelona.
32. Park SY et al. Clin Reprod Med 2016; 43: 215–20.
33. Petraglia F et al. Arch Gynecol Obstet 2012; 285: 167–73.
34. Ota Y et al. J Endometr Pelvic Pain Disord 2015; 7: 63–7.
35. Momoeda M et al. J Obstet Gynaecol Res 2009; 35: 1069–76.
36. Sugimoto K et al. J Obstet Gynaecol Res 2015; 41:1921–26.
37. Roemer T. Poster 1575 at SEUD 12–14 May 2016, Barcelona.
38. Kitawaki J et al. Eur J Obstet Gynecol Biol 2011; 157: 212–16.
39. Takagi H et al. Abstract 0671 at FIGO, 7–12 October 2012, Rome.
40. Kim SH. Poster at SEUD, 25–28 April 2018, Flolence.
41. Lee BS. Poster at SEUD, 25–28 April 2018, Flolence.
42. Imthurn B. Poster at SEUD, 25–28 april 2018, Flolence.
43. Клинические рекомендации по лечению эндометриоза. Минздрав России, 2016.
[Klinicheskie rekomendatsii po lecheniiu endometrioza. Minzdrav Rossii, 2016 (in Russian).]
________________________________________________
2. Pinzauti S, Lazzeri L, Tosti С et al. Transvaginal sonographic features of diffuse adenomyosis in 18–30-year-old nulligravid women without endometriosis: Association with symptoms. Ultrasound Obstet Gynecol 2015; 46: 730–6.
3. Naftalin J, Hoo W, Pateman K et al. How common is adenomyosis? A prospective study of prevalence using transvaginal ultrasound in a gynaecology clinic. Hum Reprod 2012; 27: 3432–9.
4. Chapron C, Tosti C, Marcellin L et al. Relationship between the magnetic resonance imaging appearance of adenomyosis and endometriosis phenotypes. Hum Reprod 2017; 32: 1393–401.
5. Puente JM, Fabris A, Patel J et al. Adenomyosis in infertile women: prevalence and the role of 3D ultrasound as a marker of severity of the disease. Reprod Biol Endocrinol 2016; 14: 60.
6. Kunz C et al. Adenomyosis in endometriosis-prevalence and impact on Fertility. Evidence From magnetic resonance imaging. Hum Reprod 2005; 20 (8): 2309–16.
7. Vered H. Eisenberg et al. Sonographic Signs oF Adenomyosis Are Prevalent in Women Undergoing Surgery For Endometriosis and May Suggest a Higher Risk oF Infertility. BioMed Res Int 2017; Article ID 8967803.
8. Tremellen K, Thalluri V. Impact of adenomyosis on pregnancy rates in IVF treatment. Reprod Biomed Online 2013; 26 (3): 299–300.
9. Bruun MR et al. Endometriosis and adenomyosis are associated with increased risk of preterm delivery and a small for gestational age child: A systematic review and meta-analysis. Acta Obstet Gynecol Scand 2018; 97 (9):1073–90. DOI: 10.1111/aogs.13364
10. Krentel et al. 2013.
11. Yeh C-C et al. Women with adenomyosis are at higher risks of endometrial and thyroid cancers: A population-based historical cohort study. PLoS ONE 2018.
12. Vannuccini S, Tosti C, Carmona F et al. Pathogenesis of adenomyosis: An update on molecular mechanisms. Reprod Biomed Online 2017; 35: 592–601.
13. Linda М et al. Experience oFSymptoms and Disease Impact in Patients with Adenomyosis Patient. DOI: https://doi.org/10.1007/s40271-017-0284-2
14. Llarena N, Flyckt R. Strategies to preserve and optimize Fertility For patients with endometriosis. J Endom Pelvic Pain Dysord 2017; 9 (2): 98–104.
15. Maignien C, Santulli P, Gayet V et al. Prognostic Factors For assisted reproductive technology in women with endometriosis-related infertility. Am J Obstet Gynecol 2017; 216 (280): e1-9.
16. Abdul Karim AK, Shafiee MN, Abd Aziz NH et al. Reviewing the role of progesterone therapy in endometriosis. Gynecol Endocrinol 2019; 35 (1): 10–6.
17. Academy of Endometriosis. Vol. No. 15. (in Russian).
18. Vannuccini S et al. Role of medical therapy in the management of uterine adenomyosis. Fertil Steril 2018; 109 (3).
19. Yutaka Osuga, Haruka Fujimoto-Okabe, Atsushi Hagino. Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study. Fertil Steril 2017; 108 (4): 673–8.
20. Osuga Y, Watanabe M, Hagino A. Long-term use of dienogest in the treatment of painful symptoms in adenomyosis. J Obstet Gynaecol Res 2017; 43 (9): 1441–8.
21. Neriishi K et al. Long term dienogest administration in patients with symptomatic adenomyosis. J Obstet Gynaecol Res 2018; 44 (8):
1439–44. DOI: 10.1111/jog.13674
22. Vartanyan E et al. Endometriosis management prior to IVF. Gyn Endocrinol 2015; 21 (Suppl. 1): 42–5.
23. Vartanian E.D. et al. Konservativnaia terapiia endometrioza pri podgotovke k lecheniiu besplodiia metodom ekstrakorporal'nogo oplodotvoreniia. Ginekologiia. Endokrinologiia. 2015; 102 (1): 21–5. (in Russian).
24. Кulvasaari P et al. Effect of endometriosis on IFV/ICSI outcome: stage III/IV endometriosis worsens cumulative pregnancy and live-born rates. Hum Reprod 2005; 20 (11): 3130–5.
25. Academy of Endometriosis. Vol. No. 19. (in Russian).
26. Grandi G, Mueller M, Bersinger NA et al. Does dienogest influence the inflammatory response of endometriotic cells? A systematic review. Inflammat Res 2016; 65 (3): 183–92.
27. Louise E. Glover. Uterine natural killer cell progenitor populations predict successFul implantation in women with endometriosis-associated infertility. Am J Reprod Immunol 2018; 79: e12817.
28. Prathoomthong, Saowapak et al. The Effects of Dienogest on Macrophage and Natural Killer Cells in Adenomyosis: A Randomized Controlled Study. Int J Fertil Steril 2018; 11 (4): 279.
29. Balan V.E. et al. Neinvazivnye markery endometrioza i dinamika ikh urovnia na fone gormonal'noi terapii. Problemy reproduktsii. 2018; 5 (in Russian).
30. Vercellini P et al. Estrogen-progestins and progestins For the management of endometriosis. Fertil and Steril 2016; 106 (7).
31. Yarmolinskay M et al. Poster at SEUD, 12–14 May 2016, Barcelona.
32. Park SY et al. Clin Reprod Med 2016; 43: 215–20.
33. Petraglia F et al. Arch Gynecol Obstet 2012; 285: 167–73.
34. Ota Y et al. J Endometr Pelvic Pain Disord 2015; 7: 63–7.
35. Momoeda M et al. J Obstet Gynaecol Res 2009; 35: 1069–76.
36. Sugimoto K et al. J Obstet Gynaecol Res 2015; 41:1921–26.
37. Roemer T. Poster 1575 at SEUD 12–14 May 2016, Barcelona.
38. Kitawaki J et al. Eur J Obstet Gynecol Biol 2011; 157: 212–16.
39. Takagi H et al. Abstract 0671 at FIGO, 7–12 October 2012, Rome.
40. Kim SH. Poster at SEUD, 25–28 April 2018, Flolence.
41. Lee BS. Poster at SEUD, 25–28 April 2018, Flolence.
42. Imthurn B. Poster at SEUD, 25–28 april 2018, Flolence.
43. Klinicheskie rekomendatsii po lecheniiu endometrioza. Minzdrav Rossii, 2016 (in Russian).
Авторы
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.